WUXI BIO shares surged 5.10% during intraday trading on Monday, extending a rally driven by the company's recent acquisition announcement and upbeat sentiment across the CXO sector.

The gains follow the August 7 disclosure of a definitive agreement to acquire Transcenta Therapeutics' process development and production base in Hangzhou. The facility is expected to enhance WUXI BIO's integrated end-to-end service capabilities, covering drug substance development, production, and drug product manufacturing. CEO Dr. Zhisheng Chen noted the acquisition further strengthens the company's comprehensive service offering.

Broader sector momentum also provided support after peer WuXi AppTec reported robust first-half results, with revenue rising 38.93% year-over-year and adjusted net profit surging 89.39%. Investors remain optimistic ahead of WUXI BIO's board meeting scheduled for August 25 to review interim results. Other CXO stocks also advanced, with WUXI APPTEC up 4.52%, XTALPI up 8.41%, and INSILICO up 7.35%.